<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inhibition of platelet aggregation is indispensable for the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> arterial thrombotic episodes </plain></SENT>
<SENT sid="1" pm="."><plain>We have previously reported the synthesis of a highly constrained <z:chebi fb="0" ids="23449">cyclic peptide</z:chebi>, that incorporates the -CDC- sequence, (S,S) PSRCDCR-NH(2), which potently inhibits aggregation and fibrinogen binding to human platelets in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>We have tested the safety and efficacy of the <z:chebi fb="7" ids="16670">peptide</z:chebi> on the electrically induced carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> experimental rabbit model </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="7" ids="16670">peptide</z:chebi>'s effects on carotid blood flow, <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight, in vitro and ex vivo platelet aggregation, and <z:mp ids='MP_0001914'>bleeding</z:mp> and hemostatic parameters were evaluated </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="7" ids="16670">peptide</z:chebi> was administered via the femoral vein </plain></SENT>
<SENT sid="5" pm="."><plain>Carotid blood flow was continuously monitored for 90 min after electrical <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:chebi fb="7" ids="16670">peptide</z:chebi>, at 12 mg/kg, prevented total <z:mp ids='MP_0006134'>artery occlusion</z:mp> and significantly preserved carotid artery's patency compared with placebo and eptifibatide </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, (S,S) PSRCDCR-NH(2) administration at 12 mg/kg reduced <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight, whereas it inhibited ex vivo <z:chebi fb="13" ids="16761">ADP</z:chebi>, <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> (AA) and collagen-induced platelet aggregation </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover (S,S) PSRCDCR-NH(2) at 12 mg/kg presented significantly higher inhibitory effects on AA and collagen-induced ex vivo platelet aggregation compared to eptifibatide </plain></SENT>
<SENT sid="9" pm="."><plain>The <z:chebi fb="7" ids="16670">peptide</z:chebi> at any dose did not affect the coagulation cascade, the <z:mp ids='MP_0001914'>bleeding</z:mp> times or the hemostatic response of the animals </plain></SENT>
<SENT sid="10" pm="."><plain>Thus highly constrained <z:chebi fb="0" ids="23449">cyclic peptides</z:chebi> like (S,S) PSRCDCR-NH(2) that incorporate the -CDC- motif and fulfil certain conformational criteria represent novel compounds that potently inhibit <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, ex vivo platelet aggregation and carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> superiorly to other non-RGD <z:chebi fb="7" ids="16670">peptides</z:chebi>, such as YMESRADR, without causing hemorrhagic complications in a rabbit model of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
</text></document>